Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Immunol. 2016 Jan 28;164:85–94. doi: 10.1016/j.clim.2016.01.015

Figure 4. Salivary B cells are dramatically reduced in BAFFR-Fc and anti-CXCL13/BAFFR-Fc treated animals.

Figure 4

Immunohistochemical staining was performed for CD3 (brown) and B220 (red) (Left panels). Spectral unmixing was performed to distinguish T (green) and B cells (red). Hematoxylin stained cells are shown in blue (right panels). (A) I.C. treated animals (n = 3) (B) BAFFR-Fc animals (n = 3), and (C) Anti-CXCL13/BAFFR-Fc treated animals (n = 3). A representative photomicrograph from each treatment group is shown. Original magnification is 40X. (D) The pixel ratio of T to B cells for each treatment group. (E) CD4 and (F) CD19 transcript levels were determined by qPCR using SMG tissue from I.C. (n = 8), BAFFR-Fc (n = 5) and anti-CXCL13/BAFFR-Fc (n = 8). I.C. = isotype control. Each sample was analyzed in duplicate and expression normalized to β-Actin. Significance was determined using Mann-Whitney test. Mean and SEM are shown (**p < 0.01, ***p < 0.001, N.S. non-significant).